• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ReWalk Robotics Confirms Receipt of Director Candidate Nominations from Creative Value Capital

    5/19/22 7:55:01 AM ET
    $RWLK
    Industrial Specialties
    Health Care
    Get the next $RWLK alert in real time by email

    Shareholders Are Not Required to Take Action at This Time

    MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received notice from Creative Value Capital Limited Partnership ("CVC"), which claims to hold approximately 3% of ReWalk's outstanding shares, that it intends to nominate two candidates for election to the Company's Board of Directors (the "Board") and submit two additional proposals for consideration at the 2022 Annual Meeting of Shareholders (the "Annual Meeting"). The Board will present its recommendation regarding director nominees in the Company's definitive proxy materials, which will be filed with the Securities and Exchange Commission and mailed to all shareholders eligible to vote at the Annual Meeting. The date of the Annual Meeting has not yet been announced. Shareholders are not required to take any action at this time.

    Jeff Dykan, Chairman of the Board, commented:

    "ReWalk's Board maintains an active and open dialogue with the Company's shareholders to ensure their feedback and ideas are incorporated into our decisions and strategy. We have engaged in good faith with CVC to understand its perspectives and the qualifications of its nominees. At this point, we continue to seek a constructive resolution that spares shareholders from having to endure a costly, distracting and unnecessary proxy fight. We are focused on continuing to strengthen ReWalk's Board for the benefit of all shareholders. Notably, the October 2020 appointment of Randel Richner and the April 2022 appointment of Joseph E. Turk, Jr. exemplify our commitment to strategic Board refreshment. Both individuals possess critical skill sets in reimbursement and post-CMS commercialization, which aligns with our short and long-term needs. We look forward to engaging further with our shareholders in the days and weeks to come."

    About ReWalk Robotics Ltd.

    ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk's mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.

    ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the Unites States.

    ReStore® is a registered trademark of ReWalk Robotics Ltd. in the United States, Europe and the United Kingdom.



    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements include statements that are not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: those factors discussed under the heading "Risk Factors" in ReWalk's annual report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the "SEC") and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

    Important Additional Information

    The Company, its directors and certain of its executive officers are participants in the solicitation of proxies from the Company's shareholders in connection with the Annual Meeting. The Company intends to file a definitive proxy statement and a WHITE proxy card with the SEC in connection with any such solicitation of proxies from the Company's shareholders. SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. The Company's definitive proxy statement for the 2021 annual meeting of shareholders contains information regarding the direct and indirect interests, by security holdings or otherwise, of the Company's directors and executive officers in the Company's securities. Information regarding subsequent changes to their holdings of the Company's securities can be found in the SEC filings on Forms 3, 4 and 5, which are available on the Company's website at http://ir.rewalk.com or through the SEC's website at www.sec.gov. Information can also be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and Amendment No. 1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2021 on file with the SEC. Updated information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the definitive proxy statement and other materials to be filed with the SEC in connection with the Annual Meeting. Shareholders will be able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge on the SEC's website at www.sec.gov. Copies will also be available at no charge on the Company's website at http://ir.rewalk.com.

    Contacts

    In the U.S.

    Morrow Sodali

    Michael Verrechia / Eric Kamback, 203-658-9400

    [email protected] / [email protected]

    Longacre Square Partners

    Joe Germani / Greg Marose

    [email protected] / [email protected]

    In Israel

    Israel Tel-Aviv

    MR. Eran Yoels

    [email protected]



    Primary Logo

    Get the next $RWLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RWLK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RWLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lind Global Fund Ii Lp bought $40,089 worth of Ordinary Shares (54,917 units at $0.73) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/21/23 4:37:18 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp bought $49,516 worth of Ordinary Shares (72,818 units at $0.68) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/16/23 4:37:44 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp sold $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) and bought $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      9/28/23 4:30:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VA STAND Act introduced in the United States Senate

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today applauded the introduction of a Senate companion bill to H.R. 6373, the VA Spinal Trauma Access to New Devices (STAND) Act. The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester (D-MT), and the Ranking Member of that committee, Senator Jerry Moran (R-KS).

      3/22/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • Lifeward Announces Reverse Share Split

      Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that effective with the open of the market on Friday, March 15, 2024, the Company will complete a 1-for-7 reverse

      3/13/24 11:45:17 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy

      Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy. Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded. Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, M

      3/8/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Leadership Updates

    Live Leadership Updates

    See more
    • ReWalk Robotics Appoints Michael Lawless as Chief Financial Officer

      MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 08, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) (the "Company" or "ReWalk"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced the appointment of Michael Lawless, CPA, as Chief Financial Officer, effective September 19, 2022. Mr. Lawless brings more than 20 years of experience leading finance and investor relations activities at life science and technology companies to drive greater financial discipline, better strategic decision making, and improved access to capital. "Mike brings an extensive background in strategic finance and investor relations

      9/8/22 8:30:34 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Confirms Receipt of Director Candidate Nominations from Creative Value Capital

      Shareholders Are Not Required to Take Action at This Time MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received notice from Creative Value Capital Limited Partnership ("CVC"), which claims to hold approximately 3% of ReWalk's outstanding shares, that it intends to nominate two candidates for election to the Company's Board of Directors (the "Board") and submit two additional proposals for consideration at the 2022 Annual Meeting of Shareholders (the "Annual

      5/19/22 7:55:01 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Announces the Appointment of Joseph E. Turk, Jr. to their Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 20, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics. Ltd. (NASDAQ:RWLK) ("ReWalk" or "The Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced today that the Board has approved the appointment of Joseph Turk, Jr. to the Board of Directors, effective today. After initiating his career at McKinsey and Company, Mr. Turk has assembled an extensive history in the medical device industry beginning with his role as Director of New Business Development at Boston Scientific. Subsequently, he held multiple roles at NxStage Medical, including President, where he led all commercialization

      4/20/22 4:05:07 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by ReWalk Robotics Ltd. (Amendment)

      SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)

      9/28/23 4:30:11 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by ReWalk Robotics Ltd. (Amendment)

      SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)

      3/9/23 4:20:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by ReWalk Robotics Ltd.

      SC 13D - ReWalk Robotics Ltd. (0001607962) (Subject)

      2/22/23 5:21:58 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lind Global Fund Ii Lp bought $40,089 worth of Ordinary Shares (54,917 units at $0.73) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/21/23 4:37:18 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp bought $49,516 worth of Ordinary Shares (72,818 units at $0.68) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/16/23 4:37:44 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp sold $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) and bought $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      9/28/23 4:30:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Financials

    Live finance-specific insights

    See more
    • Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results

      Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced its financial results for the three months and full year ended December 31, 2023. Highlights of the Fourth Quarter of 2023 and Early 2024

      2/27/24 8:00:07 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company will release its fourth quarter and fiscal year-end 2023 financial results before the markets open on Tuesday, February 27, 2024. Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the f

      2/20/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Reports Third Quarter 2023 Financial Results

      Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts to Attain Medicare Payment Coverage of Exoskeletons MARLBOROUGH, Mass., BERLIN and YOKNEAM ILLIT, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its financial results for the three and nine months ended September 30, 2023. Highlights of the Third Quarter of 2023 include: Closing of ReWalk's acquisition o

      11/14/23 8:06:13 AM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    SEC Filings

    See more
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      1/30/24 4:15:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Other Events

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      12/19/23 4:04:05 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      10/13/23 4:31:13 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright reiterated coverage on ReWalk Robotics with a new price target

      HC Wainwright reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously

      3/8/21 8:24:25 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. reiterated coverage on ReWalk Robotics with a new price target

      HC Wainwright & Co. reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously

      3/1/21 7:05:13 AM ET
      $RWLK
      Industrial Specialties
      Health Care